Current and future treatments of HIV-associated dyslipidemia

Future Lipidology

Volumn 3, Issue 2, 2008, Pages 175-188

  Bennett, M T ^a   Johns, Kevin W ^a   Bondy, G P ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Anticholesteremic agents; Antiretroviral agents; Cholesterol; HIV infections; Hyperlipidemias

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; EZETIMIBE; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METFORMIN; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET THERAPY; DOSE RESPONSE; DRUG COMPETITION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXERCISE; FLUSHING; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; MYOPATHY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 47249084253     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.2.175     Document Type: Review

References (107)

1. UNAIDS: AIDS epidemic update. (2007).
2. Grunfeld C, Kotler DP, Shigenaga JK et al.: Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 90, 154-162 (1991).
3. Grunfeld C, Kotler DP, Hamadeh F, Tierney A, Wang J, Pierson RN: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 86, 27-31 (1989).
4. Hellerstein MK, Grunfeld C, Wis K et al.: Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J. Clin. Endocrinol. Metab. 76, 559-565 (1993).
5. Shor-Posner G, Basit A, Lu Y et al.: Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am. J. Med. 94, 515-519 (1993).
6. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C: The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J. Clin. Endocrinol. Metab. 76, 1423-1427 (1993).
7. Periard D, Telenti A, Sudre P et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100, 700-705 (1999).
8. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J: Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 352, 1031-1032 (1998).
9. Mulligan K, Grunfeld C, Tai VW et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 23, 35-43 (2000).
10. Petit JM, Duong M, Duvillard L et al.: HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Horm. Metab. Res. 32, 367-372 (2000).
11. Purnell JQ, Zambon A, Knopp RH et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14, 51-57 (2000).
12. Dube MP, Qian D, Edmondson-Melancon H et al.: Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin. Infect. Dis. 35, 475-481 (2002).
13. Montes ML, Pulido F, Barros C et al.: Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART frequency, characterization and risk factors. J. Antimicrob. Chemother. 55, 800-804 (2005).
14. Friis-Moller N, Weber R, Reiss P et al.: Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 17, 1179-1193 (2003).
15. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hypedipidaemia, and diabetes mellitus: a cohort study. Lancet 353, 2093-2099 (1999).
16. Stein JH, Klein MA, Bellehumeur JL et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104, 257-262 (2001).
17. Carr A, Samaras K, Burton S et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51-F58 (1998).
18. Behrens G, Dejam A, Schmidt H et al.: Impaired glucose tolerance, β cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13, F63-F70 (1999).
19. Hammer SM, Saag MS, Schechter M et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296, 827-843 (2006).
20. Shafran SD, Mashinter LD, Roberts SE: The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 6, 421-425 (2005).
21. Sanne I, Pilieto P, Squires K, Thiry A, Schnittman S: Results of a Phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J. Acquir. Immune Defic. Syndr. 32, 18-29 (2003).
22. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D: Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive padents. J. Acquir. Immune Defic. Syndr. 47(2), 161-167 (2008).
23. Johnson M, Grinsztejn B, Rodriguez C et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20, 711-718 (2006).
24. Young J, Weber R, Rickenbach M et al.: Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Antivir. Ther. 10, 585-591 (2005).
25. Liang JS, Distler O, Cooper DA et al.: HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med. 7, 1327-1331 (2001).
26. Nolan D: Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63, 2555-2574 (2003).
27. Saint-Marc T, Partisani M, Poizot-Martin I et al.: A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13, 1659-1667 (1999).
28. Anastos K, Lu D, Shi Q et al.: Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J. Acquir. Immune Defic. Syndr. 45, 34-42 (2007).
29. Fellay J, Boubaker K, Ledergerber B et al.: Prevalence of adverse events associated with potent antiretroviral treatment. Swiss HIV Cohort Study. Lancet 358, 1322-1327 (2001).
30. Galli M, Ridolfo AL, Adorni F et al.: Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 29, 21-31 (2002).
31. van Leth F, Phanuphak P, Stroes E et al.: Nevirapine and efivirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med. 1, E19 (2004).
32. Riddler S, Haubrich R, DiRienzo G: A prospective, randomized, Phase III trial of NRTI-, Pl-, and NNRTI-sparing regimens for initial treatment of HIV-1 infections - ACTG 5142. Presented at: XVI International AIDS Conference. Toronto, Canada, 13-18 August (2006) (Abstract THLB0204).
33. Haubrich R, Riddler S, DiRenzo G: Metabolic outcomes of ACTG 5142: a prospective, randomized, Phase III trial of NRTI-, PI-, NNRTI-sparing regimens for intial treatment of HTV-1 infection. Presented at: The 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 Fcbniary (2007) (Abstract 38).
34. Villarroe M, Martinez E, Riba N, Leon A, Manrique M: Lack of metabolic abnormalities and mitochondrial toxicity with enfavirtide (T-20): a double-blind, placebo-controlled, crossover study with random sequence assignation in healthy adult volunteers. Presented at: The 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Sydney, Australia, 19-21 July (2007) Abstract.
35. Tsiodras S, Mantzoros C, Hammer S, Samore M: Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch. Intern. Med. 160, 2050-2056 (2000).
36. Friis-Moller N, Sabin CA, Weber R et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349, 1993-2003 (2003).
37. Friis-Moller N, Reiss P, Sabin CA et al.: Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356, 1723-1735 (2007).
38. Holmberg SD, Moorman AC, Greenberg AE: Trends in rates of myocardial infarction among patients with HIV. N. Engl. J. Med. 350, 730-732; author reply 730-732 (2004).
39. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J. Acquir. Immune Defic. Syndr. 30, 471-477 (2002).
40. Grover SA, Coupal I, Gilmore N, Mukherjee J: Impact of dyslipidemia associated with highly active antiretroviral therapy (HAARI) on cardiovascular risk and life expectancy. Am. J. Cardiol. 95, 586-591 (2005).
41. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society: Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can. J. Carrdiol. 22, 913-927 (2006).
42. Law MG, Friis-Moller N, El-Sadr WM et al.: The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study HIV Med. 7, 218-230 (2006).
43. Dube MP, Stein JH, Aberg JA et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy. recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. 37, 613-627 (2003).
44. Schambelan M, Benson CA, Carr A et al.: Management of metabolic complications associated with antirerroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J. Acquir. Immune Defic. Syndr. 31, 257-275 (2002).
45. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
46. Batterham MJ, Brown D, Workman C: Modifying dietary fat intake can reduce serum cholesterol in HIV-associated hypercholesterolemia. AIDS 17, 1414-1416 (2003).
47. Barrios A, Blanco F, Garcia-Benayas T et al.: Effect of dietary intervention on highly active antiretroviral therapy related dyslipemia. AIDS 16, 2079-2081 (2002).
48. Gavrila A. Tsiodras S, Doweiko J et al.: Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a crooss-sectional study. Clin. Inject. Dis. 36, 1593-1601 (2003).
49. Yarasheski KE, Tebas P, Stanerson B et al.: Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J. Appl. Pbysiol. 90, 133-138 (2001).
50. Saag MS, Powderly WG, Schamelan M et al.: Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Top. HIV Med. 10, 47-51 (2002).
51. Drechsler H, Powderly WG: Switching effective antiretroviral therapy: a review. Clin. Infect. Dis. 35, 1219-1230 (2002).
52. Milinkovic A, Martinez E, Lopez S et al.: The impact of reducing stavudine dose versus switching to tenofavir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir. Ther. 12, 407-415 (2007).
53. Llibre JM, Domingo P, Palacios R et al.: Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 20, 1407-1414 (2006).
54. Valdez JR, Cassetti I, Suleiman JM et al.: The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. HIV Clin. Trials 8, 381-390 (2007).
55. Bennett MT, Johns KW, Bondy GP: Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis. 6, 15 (2007).
56. Wohl DA, Tien HC, Busby M et al.: Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin. Infect. Dis. 41, 1498-1504 (2005).
57. Carter VM, Woolley I, Jolley D, Nyulasi I, Mijch A, Dart A: A randomised controlled trial of omega-3 fatty acid supplementation for the treatment of hypertriglyceridemia in HIV-infected males on highly active antiretroviral therapy. Sex. Health 3, 287-290 (2006).
58. Brown BG, Zhao XQ, Chair A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583-1592 (2001).
59. Istvan ES, Deisenhofer J: Structural mechanism fbr statin inhibition of HMG-CoA reductase. Science 292, 1160-1164 (2001).
60. Knopp RH: Drug treatment of lipid disorders. N. Engl. J. Med. 341, 498-511 (1999).
61. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al.: Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569-577 (2002).
62. Gerber JG, Rosenkranz SL, Fichtenbaum CJ et al.: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune Defic. Syndr. 39, 307-312 (2005).
63. Penzak SF, Chuck SK, Stajich GV: Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 20, 1066-1071 (2000).
64. Chapman MJ, McTaggart F: Optimizing the pharmacology of statins: characteristics of rosuvastatin. Atheroscler. Suppl. 2, 33-36; discussion 36-37 (2002).
65. Aberg JA, Zackin RA, Brobst SW et al.: A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res. Hum. Retroviruses 21, 757-767 (2005).
66. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG: Dietary advice with or without pravastatin for die management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15, 1503-1508 (2001).
67. Stein JH, Merwood MA, Bellehumeur JL et al.: Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am. Heart J. 147, E18 (2004).
68. Benesic A, Zilly M, Kluge F et al.: Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 32, 229-233 (2004).
69. Edwards JE, Moore RA: Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam. Pract. 4, 18 (2003).
70. Sekar V, Spinosa-Guzman S, Marien K et al.: Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin. Presented at: The 8th International Workshop on Pharmacology of HIV Therapy. Budapest, Hungary, 16-18 April (2007) (Abstract).
71. Kapur NK: Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev. Cardiovasc. Ther. 5, 161-175 (2007).
72. Calza L, Colangeli V, Manfredi R et al.: Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 19, 1103-1105 (2005).
73. Johns KW, Bennett MT, Bondy GP: Are HIV+ patients resistant to statist therapy? Lipids Health Dis. 6, 27 (2007).
74. Van Der Lee M, Vogel M, Schippers E et al.: Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Presented at: The 13th Conference on Retroviruser and Opportunistic Infections. Denver, CO, USA, 5-8 February (2006) (Abstract 588).
75. Asberg A, Holdaas H: Fluvastatin and fluvastatin extended release: a clinical and safety profile. Expert Rev. Cardiovasc. Ther. 2, 641-652 (2004).
76. Doser N, Kubli S, Telenti A et al.: Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS 16, 1982-1983 (2002).
77. Palacios R, Santos J, Gonzalez M et al.: Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 30, 536-537 (2002).
78. Murillas J, Martin T, Ramos A, Potrero JL: Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS 13, 1424-1425 (1999).
79. Bonnet F, Balestre E, Thiebaut R et al.: Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med. 5, 133-139 (2004).
80. Calza L, Manfredi R, Chiodo F: Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 17, 851-859 (2003).
81. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG: Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am. J. Cardiol. 91, 11C-17C; discussion 17C-19C (2003).
82. Palacios R, Santos J, Gonzalez M et al.: Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31, 251-253 (2002).
83. Badiou S, De Boever MC, Dupuy, AM, Baillat V, Cristol JP, Reynes J: Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 172, 273-279 (2004).
84. Caramelli B, de Bernoche CY, Sartori AM et al.: Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz. J. Infect. Dis. 5, 332-338 (2001).
85. Hewitt RG, Shelton MJ, Esch LD: Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS 13, 868-869 (1999).
86. Miller J, Brown D, Amin J et al.: A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertiglyceridaemia. AIDS 16, 2195-2200 (2002).
87. Rao A, D'Amico, S, Balasubramanyam A, Maldonado M: Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystophy. Am. J. Med. Sci. 327, 315-318 (2004).
88. Manfredi R, Chiodo F: Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J. Infect. 42, 181-188 (2001).
89. Calza L, Manfredi R, Chiodo F: Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 30, 26-31 (2002).
90. Calza L, Manfredi R, Colangeli V et al.: Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19, 1051-1058 (2005).
91. Stein E, Stender S, Mata P et al.: Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J. 148, 447-455 (2004).
92. Farnier M, Freeman MW, Macdonell G et al.: Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26, 897-905 (2005).
93. Negredo E, Molto J, Puig J et al.: Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 20, 2159-2164 (2006).
94. Coll B, Aragones G, Parra S, Alonso-Villaverde C, Masana L:- Ezedmibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 20, 1675-1677 (2006).
95. Gerber MT, Mondy KE, Yarasheski KE et al.: Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin. Infect. Dis. 39, 419-425 (2004).
96. De Truchis P, Kirstetter M, Perier A et al.: Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J. Acquir. Immune Defic. Syndr. 44, 278-285 (2007).
97. Gerber JG, Kitch DW, Fichtenbaum CJ et al.: Fish oil and fenofibrate fbr the treatnient of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J. Acquir. Immune Defic. Syndr. doi: 10.1097/QA1.Ob013e31815bace2 (2007) (Epub ahead of print).
98. Bailey CJ: Biguanides and NIDDM. Diabetes Care 15, 755-772 (1992).
99. Hadigan C, Corcoran C, Basgoz N, Davis P Sax B, Grinspoon S: Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 284, 472-477(2000).
100. Hadigan C, Rabe J, Grinspoon S: Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. J. Clin. Endocrinol. Metab. 87, 4611-4615 (2002).
101. Tomazic J, Karner P, Vidmar L, Maticic M, Sharma PM, Janez A. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta Dermatovenerol. Alp. Panonica. Adriat. 14, 99-105 (2005).
102. Yki-Jarvinen H: Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118 (2004).
103. Cavalcanti RB, Raboud J, Shen S, Kain KC, CheungA, Walmsley S: A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J. Infect. Dis. 195, 1754-1761 (2007).
104. Carr A, Workman C, Carey D et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363, 429-438 (2004).
105. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann. Intern. Med. 140, 786-794 (2004).
106. LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005).
107. Dube MP, Wu JW, Aberg JA et al.: Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Antivir. Ther. 11, 1081-1089 (2006).